GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Shiller PE Ratio

Arch Biopartners (TSXV:ARCH) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arch Biopartners Shiller PE Ratio Historical Data

The historical data trend for Arch Biopartners's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Shiller PE Ratio Chart

Arch Biopartners Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arch Biopartners Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arch Biopartners's Shiller PE Ratio

For the Biotechnology subindustry, Arch Biopartners's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Biopartners's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Shiller PE Ratio falls into.



Arch Biopartners Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Arch Biopartners's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Arch Biopartners's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.013/125.0724*125.0724
=-0.013

Current CPI (Dec. 2023) = 125.0724.

Arch Biopartners Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.001 98.604 -0.001
201406 -0.003 99.473 -0.004
201409 -0.003 99.394 -0.004
201412 -0.007 98.367 -0.009
201503 -0.003 99.789 -0.004
201506 -0.003 100.500 -0.004
201509 -0.003 100.421 -0.004
201512 -0.003 99.947 -0.004
201603 -0.006 101.054 -0.007
201606 -0.003 102.002 -0.004
201609 -0.007 101.765 -0.009
201612 -0.004 101.449 -0.005
201703 -0.003 102.634 -0.004
201706 -0.024 103.029 -0.029
201709 -0.004 103.345 -0.005
201712 -0.006 103.345 -0.007
201803 -0.011 105.004 -0.013
201806 -0.026 105.557 -0.031
201809 -0.010 105.636 -0.012
201812 -0.014 105.399 -0.017
201903 -0.009 106.979 -0.011
201906 -0.001 107.690 -0.001
201909 -0.012 107.611 -0.014
201912 -0.012 107.769 -0.014
202003 -0.002 107.927 -0.002
202006 -0.037 108.401 -0.043
202009 -0.026 108.164 -0.030
202012 -0.027 108.559 -0.031
202103 -0.017 110.298 -0.019
202106 0.013 111.720 0.015
202109 0.011 112.905 0.012
202112 -0.003 113.774 -0.003
202203 -0.008 117.646 -0.009
202206 -0.004 120.806 -0.004
202209 -0.008 120.648 -0.008
202212 -0.035 120.964 -0.036
202303 -0.015 122.702 -0.015
202306 -0.007 124.203 -0.007
202309 0.004 125.230 0.004
202312 -0.013 125.072 -0.013

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arch Biopartners  (TSXV:ARCH) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Arch Biopartners Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Biopartners (TSXV:ARCH) Business Description

Traded in Other Exchanges
N/A
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.